Susan Guba

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Review · Drug Designing Open Access · 2015 · 537 citations

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and…

Journal of Clinical Oncology · 2013 · 306 citations